SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-011916
Filing Date
2024-02-08
Accepted
2024-02-08 06:59:42
Documents
6
Period of Report
2024-03-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm242558-2_def14a.htm DEF 14A 1029359
2 GRAPHIC bc_companytsr-4c.jpg GRAPHIC 52989
3 GRAPHIC bc_netincome-4c.jpg GRAPHIC 50617
4 GRAPHIC lg_outlooktherapeutics-4clr.jpg GRAPHIC 18730
5 GRAPHIC px_24outlkpxy01pg01-bwlr.jpg GRAPHIC 432045
6 GRAPHIC px_24outlkpxy01pg02-bw.jpg GRAPHIC 313271
  Complete submission text file 0001104659-24-011916.txt   2196356
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 24606819
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)